New treatment for a type of brain cancer in children
Nanoformulated small molecule immunotherapy for SHH medulloblastoma
This study is testing a new treatment for children with SHH medulloblastoma, a type of brain cancer, using a special drug that helps the immune system fight the cancer while aiming to cause fewer side effects than current therapies.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of North Carolina Chapel Hill NIH-funded |
| Lab location | 1 site (Chapel Hill, United States) |
| Project ID | NIH-11004378 on NIH RePORTER |
What this research studies
This research focuses on developing a new immunotherapy using nanoformulated small molecules to treat SHH medulloblastoma, a type of brain cancer in children. The approach aims to enhance the effectiveness of treatment while reducing the severe side effects associated with current therapies. By utilizing the body's immune system, the researchers hope to create a safer and more effective option for patients. The study will evaluate a specific drug, resiquimod, which targets immune cells in the tumor environment to improve patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are children diagnosed with SHH medulloblastoma who are undergoing treatment or have had recurrent disease.
Not a fit: Patients with other types of brain tumors or those who are not diagnosed with SHH medulloblastoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a safer and more effective treatment option for children with SHH medulloblastoma, potentially improving survival rates and quality of life.
How similar studies have performed: Previous studies have shown promise in using immunotherapy for various cancers, indicating potential success for this novel approach in treating SHH medulloblastoma.
Where this research is happening
Chapel Hill, United States
- Univ of North Carolina Chapel Hill — Chapel Hill, United States (Active)
Researchers
- Principal investigator: Sokolsky-Papkov, Marina — Univ of North Carolina Chapel Hill
- Study coordinator: Sokolsky-Papkov, Marina
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.